Heart-Drug Breakthroughs Can’t Stop Biotech Stocks From Sliding
Impressive results came out on drugs from Amgen, Arrowhead Pharmaceuticals, and Crispr Therapeutics. Their shares are all lower this week.
Yahoo Finance
Updated Sep 1, 2026
Upgrade to a paid plan to see AI rating history on the chart.
Impressive results came out on drugs from Amgen, Arrowhead Pharmaceuticals, and Crispr Therapeutics. Their shares are all lower this week.
Jim Cramer is flagging an Amgen drug that Wall Street has largely ignored, and he thinks the cardiovascular opportunity behind it could rival the most valuable…
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines thro…
Amgen said Monday its cholesterol buster, Repatha, reduced the risk of death by 20% in a study of more than 12,000 high-risk patients.
AbbVie, Tandem Diabetes Care and Amgen are targeting aging-related healthcare growth through advances in immunology, diabetes and cardiovascular care.
AMGN has outperformed the broader market over the past year, while analysts remain moderately bullish on its future prospects.
The global palmoplantar pustulosis market is expanding as awareness, diagnosis rates and demand for targeted biologic therapies increase. Advances in IL-23 and…
The global non-melanoma skin cancer (NMSC) market is growing as basal cell carcinoma and squamous cell carcinoma rates rise due to UV exposure and aging popula…
Not investment advice. Past performance does not guarantee future results. Full disclaimer